Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for TXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 16.97M
March 31, 2026 26.12M
December 31, 2025 40.78M
September 30, 2025 43.21M
June 30, 2025 17.71M
March 31, 2025 34.35M
December 31, 2024 -6.748M
September 30, 2024 21.64M
June 30, 2024 7.496M
March 31, 2024 -15.72M
December 31, 2023 25.76M
September 30, 2023 -25.30M
June 30, 2023 -11.53M
March 31, 2023 -4.125M
Date Value
December 31, 2022 13.72M
September 30, 2022 -9.564M
June 30, 2022 -16.96M
March 31, 2022 -20.80M
December 31, 2021 5.805M
September 30, 2021 -26.22M
June 30, 2021 3.12M
March 31, 2021 -4.082M
December 31, 2020 -130.18M
September 30, 2020 -55.63M
June 30, 2020 -29.52M
March 31, 2020 -2.576M
December 31, 2019 6.70M
September 30, 2019 14.53M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Twist Bioscience Corp. 1.115M
Alamar Biosciences, Inc. (California) -11.32M
Personalis, Inc. -25.77M
Adaptive Biotechnologies Corp. -6.40M
Tempus AI, Inc. -8.05M